Iterum Therapeutics is a Dublin-based clinical-stage pharmaceutical company developing sulopenem, a novel oral and intravenous penem antibiotic targeting Gram-negative multi-drug resistant infections. Sulopenem has demonstrated broad-spectrum coverage and potent in-vitro activity against Enterobacteriaceae (ESBL) mutants of E. coli and K. pneumoniae, with a safety and efficacy profile similar to other penems. The company’s initial indications of interest are uncomplicated urinary tract infections, complicated urinary tract infections and complicated intra-abdominal infections (uUTI, cUTI and cIAI). Iterum is led by CEO Corey Fishman and CSO Michael Dunne, MD. The company raised capital to fund late-stage development and plans to use proceeds to complete a Phase 3 pivotal trial in uUTI and to advance a broader Phase 3 pivotal program. Trials were expected to begin in the first half of 2018 and Iterum planned to file an NDA with the FDA by year-end 2019. Iterum Therapeutics Limited is a Dublin, Ireland–based clinical-stage pharmaceutical company focused on developing and commercializing differentiated anti-infectives. Its lead asset is a novel anti-infective compound for which it has licensed global rights from a multinational pharmaceutical company. The compound has demonstrated potent in‑vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria, including strains resistant to other antibiotics. Iterum is led by CEO Corey Fishman and Chief Scientific Officer Dr. Michael Dunne. The company intends to use the new funding to support licensing and product development activities.

Total raised

$105M

Funding rounds

2

Latest round

Series B

Latest activity

May 2017